<DOC>
	<DOCNO>NCT00191451</DOCNO>
	<brief_summary>The purpose study determine safety gemcitabine paraplatin either without trastuzumab Any side effect might associate compound . Whether two three drug list give combination help patient metastatic breast cancer . How long treatment stop growth cancer .</brief_summary>
	<brief_title>A Study Gemcitabine Carboplatin ( Plus Herceptin Human Epidermal Growth Factor Receptor 2 Positive HER2+ Patients ) With Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Taxane</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>1 . Diagnosis metastatic breast cancer 2 . Able visit doctor 's office least every 14 day actual treatment 3 . Able care , even work participate normal activity 4 . Your blood result must adequate therapy . 5 . If female childbearing potential test negative pregnancy , use reliable method birth control three month follow last dose study drug . 1 . Have receive gemcitabine , paraplatin , trastuzumab cancer . 2 . Be pregnant breastfeed 3 . Have cancer brain treat 4 . Have another active cancer besides breast cancer 5 . Have receive stem cell bone marrow transplant hematologic ( blood type ) cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>